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Abstract: Noninvasive simple scores have been validated to assess advanced liver fibrosis in patients
with nonalcoholic fatty liver disease (NAFLD). We performed a systematic review with meta-analysis
evaluating if NAFLD fibrosis score (NFS), AST to platelet ratio index (APRI), and Fibrosis-4 (FIB-4)
score may also predict mortality. PubMed and EMBASE databases were searched until April 2018.
Random-effects models were used to calculate pooled RRs of mortality for highest vs. lowest
categories of exposure and to perform dose-response meta-analysis. Heterogeneity was assessed
using the Q test and I2 statistic. Overall, eight studies were included in the systematic review; all of the
eight studies provided data for NFS, while four provided data for APRI and FIB-4. When comparing
the risk estimates for high (>0.676) vs. intermediate + low NFS (≤0.676), we found a nearly fourfold
increase in mortality risk, with evidence of heterogeneity (RR = 3.85, 95% CI: 2.08, 7.11; I2 = 92%).
At dose-response meta-analysis, compared to the midpoint of the lowest category of NFS (−2.5),
the risk of mortality was about twofold higher for NFS = −0.5 (RR = 2.20, 95% CI: 1.31, 3.70) and
more than fivefold higher for NFS = 1.5 (RR = 5.16, 95% CI: 2.02, 13.16). When comparing the
risk estimates for high (>1.5) vs. medium + low APRI (≤1.5), we found a higher risk of mortality,
without heterogeneity (RR = 3.61, 95% CI: 1.79, 7.28; I2 = 0%). Comparison of the risk estimates for
high (>2.67) vs. medium + low FIB-4 (≤2.67) didn’t reveal a significantly higher risk of mortality,
with heterogeneity (RR = 2.27, 95% CI: 0.72, 7.15; I2 = 85%). Dose-response analysis for APRI and
FIB-4 was not considered conclusive due to the low number of studies. Based on the results of our
meta-analysis, the measurement of NFS can be considered an accurate tool for the stratification of the
risk of death in patients with NAFLD.
Keywords: NAFLD fibrosis score; APRI; FIB-4; mortality
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) has become a major health problem worldwide because
of its potential to evolve into cirrhosis and hepatocellular carcinoma (HCC) [1]. Epidemiological studies
from different countries have indicated that fibrosis is the best predictor of liver-related and overall
mortality in patients with NAFLD [2]. For this reason, a main goal in the management of NAFLD
patients is to identify those at higher risk of clinically significant fibrosis, as also recently underlined
in AASLD (American Association for the Study of Liver Diseases) practice guidance and EASL
(European Association for the Study of the Liver) guidelines [3,4]. Obviously, liver biopsy is unsuitable
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for screening of clinically significant fibrosis for a condition that affects at least 30% of adult people in
industrialized countries [1].
In the last decade, different noninvasive blood-based and imaging-based biomarkers have
been developed and validated for the assessment of liver fibrosis in patients with NAFLD [5,6].
Simple blood-based scores including routine parameters can be easily obtained and thus are suitable
also in the primary care setting. Among them, the NAFLD fibrosis score (NFS) [7] that can be easily
calculated online (http://nafldscore.com/) has shown a good performance for detecting advanced
fibrosis and cirrhosis [8]. Excluding patented blood-based scores, other scores that can be easily
obtained, and thus are considered simple noninvasive scores, are APRI, FIB-4, BARD, and Forns [5].
Besides prediction of clinically significant fibrosis, in the last five years, retrospective and
prospective studies have evaluated the predictive value of simple scores of fibrosis for clinically relevant
outcomes such as liver events/transplantation and general mortality [9–16]. Here we performed
a systematic review with meta-analysis of these studies.
2. Methods
2.1. Search Strategy
We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) checklist [17] for transparent reporting in systematic reviews and meta-analyses
(Supplementary Figure S1). A comprehensive literature search was conducted using two databases:
PubMed and EMBASE; databases were screened up to April 2018, with a restriction to publications
in English. The following search terms were used: (NAFLD OR nonalcoholic fatty liver disease
OR non-alcoholic fatty liver disease OR fatty liver OR liver steatosis OR NASH OR nonalcoholic
steatohepatitis OR non-alcoholic steatohepatitis OR steatohepatitis) AND (mortality OR survival OR
death) AND (cohort OR cross-sectional OR longitudinal OR retrospective). Two authors (FS, JG)
independently screened titles and abstracts of all identified studies. Discrepancies were resolved by
consensus. Additionally, the reference lists of retrieved articles were hand searched to identify studies
not previously detected. When duplicate reports on the same cohort were identified, the one with
the largest number of cases/entire cohort or with the longest follow-up for endpoint of interest was
included. Eligibility criteria for study inclusion in the meta-analysis were based on the following
criteria: (i) study design: cohort study with prospective or retrospective design; (ii) population
with a diagnosis of NAFLD; (iii) mortality as the endpoint outcome; (iv) the measure of association
(relative risk, odds ratio, hazard ratio) with 95% confidence interval between scores and mortality.
2.2. Data Extraction
Using a standardized extraction form, data were abstracted from all identified studies.
The following information was obtained from each article: (1) first author name; (2) year of publication;
(3) study design; (4) country; (5) name or type of cohort; (6) age range of the study population at
baseline; (7) tool used for NAFLD diagnosis; (8) follow-up period; (9) number of cases; (10) dose
for each category of exposure; (11) relative risks or hazard ratios, with 95% CI; (12) covariates used
in adjustments.
2.3. Statistical Analysis
In this meta-analysis, ORs and HRs were deemed equivalent to RRs. Random-effects models
were used to calculate pooled RRs (with 95% CIs) of mortality for highest vs. lowest categories of
exposure and for dose-response analysis [18] (Supplementary methods). Heterogeneity was assessed
using the Q test and I2 statistic. The significance for the Q test was defined as p < 0.10. The I2 statistic
represents the sum of total variation that could be attributed to heterogeneity. I2 values ≤ 25%, 25–50%,
50–75% and >75% indicated no, small, moderate, and high heterogeneity, respectively. A sensitivity
analysis, where possible, was conducted by excluding one study at the time to assess the stability
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of results. Subgroup analyses were conducted by study design, geographical location, tool used
for NAFLD diagnosis, and adjustment for confounding factors. Publication bias was assessed by
visual observation of funnel plot (Supplementary Figure S2). All analyses were performed with
Review Manager (RevMan) version 5.2.
3. Results
The search identified 1254 studies, of which 1037 were excluded after reviewing the title,
and 202 after reviewing the abstract (Figure 1). Of the 15 publications selected for the evaluation
of full-text article, 7 were excluded for the following reasons: (1) article did not provide risk with
confidence intervals; (2) article did not have prospective or retrospective design; (3) article provided
data for the association between NAFLD and mortality, but not for scores; (4) mortality was not the
endpoint outcome; (5) article reported on other scores/indexes.
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For the systematic review on the association between noninvasive scores of fibrosis and mortality
in NAFLD patients, eight studies were eligible [9–16]. All the eight articles provided data for
NFS [9–16], and 4 articles for APRI and FIB-4 [9,11,13,14]. Selected characteristics of the studies
included in the systematic review are described in Table 1 and Supplementary Table S1. Among the
J. Clin. Med. 2018, 7, 219 4 of 10
eight studies, only one study provided data for mortality for BARD [11] and one for Forns [14],
and thus these two scores were not considered for the meta-analysis.
Table 1. Main features of the 8 studies included in the systematic review (NA: not avalaible).
Author, Year,
Country
Cohort, Study
Design
Number of
Participants Age
Male
Gender
Follow-up
Duration
NAFLD
Diagnosis
Kim, 2013, USA Population-based,prospective
4081 NAFLD
individuals with
available APRI,
FIB-4, NFS
45.5 years
(mean) 50.3%
14.5 years
(median) Ultrasonography
Treeprasertsuk,
2013, USA
Community-based,
retrospective
302 NAFLD
individuals with
available NFS
47.3 years
(mean) 44%
12 years
(mean) Liver biopsy
Angulo, 2013,
Multi-country
Hospital-based,
multicenter,
retrospective
320 NAFLD
individuals with
available APRI,
FIB-4, NFS
52 years
(median) 43%
8.7 years
(104.8
months)
(median)
Liver biopsy
Xun, 2014,
China
Hospital-based
single center,
retrospective
180 NAFLD
individuals with
available APRI,
FIB-4, NFS
39 years
(median) 53.3%
6.6 years
(median) Ultrasonography
Sebastiani, 2015,
Canada
Hospital-based
single center,
retrospective cohort
148 NAFLD
individuals with
available NFS
49.5 years
(mean) 69.6%
5 years
(median) Liver biopsy
Unalp-Arida,
2017, USA
Population-based,
prospective
14841 individuals
for APRI and FIB-4,
14741 for NFS
NA NA 19.3 years(median)
Negative for
viral hepatitis
markers
Le, 2017, USA Population-based,prospective
1936 NAFLD
individuals with
available NFS
53.2 years
(mean) 59.2%
13 years (up
to)
United States
Fatty Liver
Index (USFLI)
Yoshihisa, 2017,
Japan
Hospital-based
single center,
prospective
492 patients with
heart failure and
preserved ejection
fraction
NA NA
3.0 years
(1096 days)
(mean)
Not assessed
Briefly, 4 studies were prospective cohorts [9,14–16], while others were retrospective
studies [10–13]. Three studies included patients with biopsy-proven NAFLD [10,11,13]; two studies
included patients with liver steatosis diagnosed by ultrasonography [9,12] and two studies included
patients with a diagnosis of NAFLD based on serum markers [14,15]; one study did not assess the
presence of NAFLD [16]. Six studies adjusted for potential confounding factors [9,11,13–16] and
two did not [10,12]. Five studies were conducted in North America [9,10,13–15], two in Asia [12,16],
and one study was multicountry [11]. The median follow-up ranged from 3 to about 19 years.
3.1. NAFLD Fibrosis Score
Among the eight studies, six provided data for the high vs. intermediate-low analysis [10–15].
The study by Kim et al. [9] was excluded because the same NHANES cohort with a longer follow-up
was analyzed by Unalp-Arida five years later [14]. The study by Yoshihisa et al. [16] was included in
the dose-response analysis but was excluded from the high vs. intermediate + low analysis because it
used cut-points for NFS that were different from cut-points used in all other studies. When comparing
the risk estimates for high (>0.676) vs. intermediate-low NFS (≤0.676), we found a nearly fourfold
increase in risk of mortality (RR = 3.85, 95% CI: 2.08, 7.11; I2 = 92%), with evidence of heterogeneity
(Figure 2, Panel A). The results were similar in the analysis comparing high (>0.676) vs. low NFS
(<−1.455) (RR = 4.44, 95% CI: 2.11, 9.35; I2 = 87%) (Figure 2, Panel B). In this latter analysis, Sebastiani
et al. [13] was not included because it reported only NFS > 0.676 vs. ≤ 0.676.
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Heterogeneity was due to he r sults of Unalp-Arida’s study [14] that reported substantial lower
risk stimat compared to other studies; a pot ntial reason for such findings is that authors assessed
the pre ic ive value of noninvasive scores in a general NHANES population of virus-negative
individuals [14]. However, after exclusion of this study in e sensitivity analy s, overall ri k
estim te remained significant and heteroge eity decreas d (RR = 4.49, 95% CI: 3.08, 6.54; I2 = 41%,
Pheterogeneity = 0.15). The subgroup analysis showed a tr nger positive association for the studies that
included c ses diagnosed using liver biopsy (RR = 4.33, 95% CI: 1.99, .43), studies with retrospective
d sign (RR = 4.72, 95% CI: 2.50, 8.93), and studies that adjusted for confounding factors (RR = 4.45,
95% CI: 2.35, 8.43) with evidence of lo er h terogeneity (Table 2).
able 2. Subgroup analysis of the six studies included in the meta-analysis of NFS and mortality.
Subgroup No. of Studies RR (95% CI) I2 Pheterogeneity
Total 6 3.85 (2.08, 7.11) 92% <0.00001
Study design
Prospective 2 2.70 (0.98, 7.44) 98% <0.00001
Retro ctive 4 4.72 (2.50, 8.93) 55% 0.08
Geographical location
Nort erica 4 3.88 (1.80, 8.37) 95% <0.00001
Asia 1 7.00 (2.46, 19.92) NA NA
Multicountry 1 2.39 (1.20–4.76) NA NA
Liver biopsy
Yes 3 4.33 (1.99, 9.43) 64% 0.06
No 3 3.43 (1. 2, 8.28) 96% <0.00001
Adjustment for confounding factors
Yes 3 4.45 (2.35, 8.43) 67% 0.05
No 3 3.23 (1.32, 7.91) 85% 0.001
Data from six studies [10–12,14–16] were used to perform dose-response meta-analysis of risk estimates
for NFS. The analysis showed that compared to the midpoint of the lowest category of NFS (−2.5), the risk
of mortality was about twofold higher for NFS = −0.5 (RR = 2.20, 95% CI: 1.31, 3.70) and more than fivefold
higher for NFS = 1.5 (RR = 5.16, 95% CI: 2.02, 13.16) (Figure 3) (Supplementary Table S2).
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Figure 3. Dose-response association bet een AFLD fibrosis score and mortality risk in NAFLD
patients. Solid lines represent risk ratio, dashed lines represent 95% confidence intervals.
3.2. APRI and FIB4
The meta-analysis of risk estimates for the other two scores was limited by the small number of
studies includable. Concerning APRI, studies by Kim et al. [9] and Angulo et al. [11] provided data
in three categories of exposure: high (>1.5), medium (0.5–1.5) and low (<0.5), as in the study that
originally proposed the score [19]. Sebastiani et al. [13] considered only two categories of exposure:
high (>1.5) and medium-low (≤1.5). Differently, Unalp-Arida et al. [14] provided two other categories:
medium-high (>0.5) vs. low (<0.5). Thus, considering the high vs. intermediate-low analysis for
APRI, we were able to include only data from Angulo et al. [11] an Sebastiani et al. [13] but ot from
Kim et al. [9] because this latter study didn’t provi e the numbers of cas , controls, covariate-a justed
OR, and CIs that are required to pool the categories medium (0.5–1.5) and low (<0.5) toge her to obtain
the category <1.5 by the Hamling method. With d a fr m the two studies [11,13], when comparing
high (>1.5) vs. intermediate + low APRI (≤1.5), we found a higher mortality risk with no vidence of
heteroge eity (RR = 3.61, 95% CI: 1.79, 7.28; I2 = 0%) (Figure 4, Panel A).
In the analysis of high vs. low APRI, we were able to include only Angulo et al. [11] and
Kim et al. [9] because, as previously stated, Sebastiani et al. [13] considered only two categories of
exposure: high (>1.5) and medium-low (≤1.5) and again it was not possible to include data from
Unalp-Arida et al. because they used different cut-points from [19] and from the other studies used
for this meta-analysis. With data from the two studies [9,11], when comparing the risk estimates for
high (>1.5) vs. low APRI (<0.5), we found a twofold increased risk of mortality, without heterogeneity
(RR = 2.10, 95% CI: 1.25, 3.52; I2 = 0%) (Figure 4, Panel B).
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Concerning FIB-4, studies by Kim et al. [9], Angulo et al. [11], and Unalp-Arida et al. [14] provided
data in three categories of exposure: high (>2.67), medium (1.30–2.67), and low (<1.30), as in the study
that validated this score in the NAFLD setting [20]. Sebastiani et al. [13] considered two categories of
exposure (>3.25 vs. ≤3.25) in contrast with the other three vailable studies and thus was not included.
Since Unalp-Arida et al. reported dat from Kim et al. w th a longer follow-up, only data from [11]
and [14] were availabl for compariso of i (>2.67) vs. med um-low FIB-4 (≤2.67) hat didn’t reveal
a significantly higher risk of mortality, with evidence of heterogeneity (RR = 2.27, 95% CI: 0.72, 7.15;
I2 = 85%, p = 0.009) (Figure 5, Panel A). Similarly, comparison of the risk estimates for high (>2.67) vs.
low FIB-4 (<1.30) didn’t show a higher risk, with evidence of heterogeneity (RR = 2.80, 95% CI: 0.59,
13.42; I2 = 88%) (Figure 5, Panel B).
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Dose-response meta-analysis of risk estimates was possible only with data from Angulo et al. [11]
for APRI and from Angulo et al. and Unalp-Arida et al. [11,14] for FIB-4 score because of missing
data on cases and non-cases in the remaining studies. Therefore, dose-response analysis for these
two scores have low power and findings cannot be considered conclusive (Supplementary Table S2;
Supplementary Figure S2).
4. Discussion
In this study, we meta-analyzed retrospective and prospective studies conducted so far, reporting
data of association between values of NFS, APRI, and FIB-4 with mortality of patients with NAFLD.
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Our meta-analysis shows that an NFS > 0.676 is associated with about a fourfold higher risk of death
as compared with a low or nonhigh value and NFS is associated with higher risk of mortality in
a dose-response manner.
Among studies included in this systematic review, the study by Kim et al. [9] was the first that
assessed the ability of simple noninvasive scores of fibrosis in predicting mortality. By analyzing data
from the National Health and Nutrition Examination Survey (NHANES), the authors showed that after
a median follow of 14.5, among a population of 11,154 individuals with an ultrasonographic diagnosis
of liver steatosis, only those with high NFS, APRI, and FIB-4 displayed an increase of mortality
with adjustment for several established predictors of mortality. Successively, Treeprasertsuk et al. [10]
reviewed retrospectively data from a histologically characterized cohort from the Mayo Clinic and
showed that a high NFS predicted all-cause mortality and cardiac and liver complications after a mean
follow-up of 12 years, although significance of their findings was limited by the absence of adjustments.
The first study considering an international, multicenter cohort was from Angulo et al. [11], who found
that high APRI and FIB-4 and both intermediate and high NFS were able to predict death and
liver-related events in a biopsy-proven cohort of 320 patients with a follow-up of almost 9 years
even after adjustments for several parameters. Xun et al. [12] confirmed the predictive value of NFS,
FIB-4, and APRI for all-cause mortality in Chinese patients after a 6.6-year median follow-up although
without any adjustment.
Sebastiani et al. [13] evaluated retrospectively a well-characterized Canadian cohort of 148 patients
with available liver biopsies and hepatic venous pressure gradient (HVPG) measures and found that
APRI > 1.5, FIB-4 > 3.25, and NFS > 0.676 did not significantly differ from histological grading and
HVPG in predicting clinical outcomes including death and liver-related complications. Recently,
three studies reported simple noninvasive scores’ predictive value for mortality with a prospective
design. In the bigger population-based study conducted so far, Unalp-Arida and Ruhl [14] analyzed
data from almost 15,000 viral hepatitis-negative adult participants in the third NHANES, 1988–1994,
and found an increased overall and liver-related mortality in individuals with a high APRI, FIB-4, Forns,
or NFS over a 19.3-year median follow-up, after adjustment for age. Similarly, Le et al. [15] analyzed
prospectively data from NHANES 1999–2012 and reported data from 1936 individuals with NAFLD as
diagnosed by the US Fatty Liver Index. Authors found that only patients with NFS > 0.676 had a higher
risker of all-cause mortality. Interestingly, this is in line with Yoshihisa et al. [16], who investigated the
association of NFS with mortality in a prospective cohort of 492 patients followed-up for heart failure
with preserved ejection fraction and found a higher risk of death with higher quartiles of NFS. It is
well established that cardiovascular diseases are the main cause of death in patients with NAFLD [2]
because of the proinflammatory and atherogenic milieu associated with liver steatosis and fibrosis.
Besides simple scores, in the last years, several other noninvasive approaches to assess fibrosis in
the daily clinical practice have been validated in NAFLD [21], including patented blood tests such as
Enhanced Liver Fibrosis (ELF) [22] or imaging-based techniques such as elastography [6]. A recent
meta-analysis has shown that magnetic resonance and shear wave elastography display the highest
diagnostic accuracy for staging fibrosis in NAFLD patients [8]. However, imaging-based techniques are
not widely available in clinical practice among general practitioners or primary healthcare providers.
Vibration-controlled transient elastography as assessed by Fibroscan™ has become a main diagnostic
tool to assess fibrosis in NAFLD, although its diagnostic accuracy is limited by steatosis degree and
other factors [8]. However, Fibroscan™ is almost exclusively diffused in the hospital setting, at least in
Italy, and thus the access to elastography needs to be filtered by primary care physicians. Consistently,
although several studies from the US are showing the elevated diagnostic accuracy of MRI elastography
for the assessment of fibrosis [6], it is reasonable that this sophisticated tool may be reserved for clinical
trials at least for the next years. By contrast, simple scores of fibrosis are widely used because they
are based on common laboratory parameters alone, such as it is for APRI, or combined with age
and body mass index, such as it is for the NFS. Results of our meta-analysis show that there is
solid evidence to recommend the clinical use of NFS because of its dose-response association with
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mortality, whereas there is less evidence for APRI and not enough evidence so far to recommend
FIB-4. For this reason, we believe that NFS calculation should be constantly performed to screen which
patients should undergo elastography or imaging-based techniques to assess fibrosis. This may be
particularly important in non-hepatological contexts (such as general practitioners, diabetologists,
and cardiologists) in which elastography or more sophisticated techniques are not widely available.
5. Conclusions
In conclusion, results from our meta-analysis suggest that the measurement of NFS can be
considered an accurate tool for the stratification of the risk of death and thus should be routinely
assessed as a screening test for fibrosis in NAFLD patients.
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